Is XBI ETF a Buy?

Is XBI ETF a Buy?

SPDR S&P Biotech ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, XBI is an outstanding option for investors seeking exposure to the Health Care ETFs segment of the market.

Is XBI actively managed?

You should consider the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on 01/31/2006.

What is the difference between IBB and XBI?

XBI is an equal-weight ETF, whereas IBB is cap weighted. That gives XBI a potential performance advantage when smaller biotech stocks are surging, but it also makes the ETF more volatile than its cap-weighted peer. XBI’s three-year annualized volatility is nearly 800 basis points higher than that of IBB.

What is XBI ETF?

XBI Top 10 Holdings[View All]

  • Arena Pharmaceuticals, Inc. 1.97%
  • BioCryst Pharmaceuticals, Inc. 1.42%
  • Exelixis, Inc. 1.26%
  • Biohaven Pharmaceutical Holding Company Ltd. 1.21%
  • AbbVie, Inc. 1.17%
  • Vertex Pharmaceuticals Incorporated 1.14%
  • Neurocrine Biosciences, Inc. 1.12%
  • Alkermes Plc 1.12%

What holdings are in XBI?

Top 10 Holdings

Company Symbol Total Net Assets
Arena Pharmaceuticals Inc. ARNA 1.70%
Biohaven Pharmaceutical Holding Co. Ltd. BHVN 1.23%
BioCryst Pharmaceuticals Inc. BCRX 1.23%
Emergent Biosolutions Inc. EBS 1.08%

Why biotech stocks are falling today?

Over the past six months, the Nasdaq Biotechnology Index has declined more than 20%. Some of the falling prices appear to be due to some investors losing interest in many companies that soared into favor during the COVID-19 pandemic.

What is the SPDR Biotech ETF?

About SPDR® S&P Biotech ETF The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index.

How many stocks are there in XBI?

Fund Characteristics as of Feb 24 2022

Number of Holdings Price/Book Ratio Price/Book Ratio The weighted harmonic average of closing market price divided by the most recent reported book value for each security in the fund’s portfolio as calculated for the last twelve months. Weighted Average Market Cap
189 3.08 $9,568.64 M

Is XBI a good buy now?

For someone looking for broad-based exposure, including a large allocation to smaller, not-yet-profitable biotech companies, XBI is one of the best choices. Someone seeking more exposure to established, profitable, lower-risk biotech majors might better pass on XBI.

What is the best genomic ETF?

Here are the seven best biotech ETFs to buy:

  • iShares Biotechnology ETF (IBB)
  • SPDR S&P Biotech ETF (XBI)
  • ARK Genomic Revolution ETF (ARKG)
  • First Trust NYSE Arca Biotechnology ETF (FBT)
  • iShares Genomics Immunology and Healthcare ETF (IDNA)
  • Invesco Dynamic BioTech & Genome ETF (PBE)

What companies are in XBI?

Top 10 Holdings

Company Symbol Total Net Assets
Arena Pharmaceuticals Inc. ARNA 1.44%
Biohaven Pharmaceutical Holding Co. Ltd. BHVN 1.07%
Cytokinetics Inc. CYTK 0.98%
Turning Point Therapeutics Inc. TPTX 0.93%

Is XBI the best pure biotech ETF to buy?

While XBI has seen a recent surge, it is not the only pure biotech ETF to pop. XBI’s competitor funds iShares Biotechnology ETF (IBB) and First Trust NYSE Arca Biotechnology Index Fund (FBT), also gained ground. IBB is +7.1% for the week, and FBT is +6%.

Is XBI on pace for its best trading week in 21 months?

The SPDR S&P Biotech ETF ( NYSEARCA: XBI) is on pace for its best trading week in 21 months as the exchange traded fund earlier this week hit a 23-month trading low. XBI is now +8.2% and +2.6% for the day. The biotech fund had not seen such bullish weekly moves since June of 2020, when it jumped 9.9%.

Is XBI still a good investment in 2022?

While XBI has risen this week, the ETF is still -18.6% in 2022 and down 47.6% from its record high of 174.79 a share dating back to February of 2021. Furthermore, XBI also trades below its pre-COVID 19 high and below its 200-day moving average by 12.1%.

What is the difference between SPDR S&P biotech ETF (XBI) and Ibb?

SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index and the iShares Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $7.14 billion in assets, iShares Biotechnology ETF has $8.55 billion. XBI has an expense ratio of 0.35% and IBB charges 0.45%.